• Yueh-Lun Lee, Didik Setyo Heriyanto, Fara Silvia Yuliani, Vincent Laiman, Lina Choridah, Kang-Yun Lee, Jer-Hwa Chang, Kian Fan Chung, Li-Te Chang, Ta-Yuan Chang, Xiao-Yue Chen, Syue-Wei Peng, Kai-Jen Chuang, and Hsiao-Chi Chuang.
• Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
• Ann. Med. 2024 Dec 1; 56 (1): 24084662408466.

BackgroundChronic Obstructive Pulmonary Disease (COPD) remains a significant public health challenge due to its high morbidity and mortality rates. Emerging research has identified eosinophilic inflammation as a crucial factor in the pathogenesis and exacerbation of COPD, warranting a detailed exploration of its underlying mechanisms and therapeutic implications.ObjectiveThis review aims to elucidate the role of eosinophils in COPD, focusing on their contribution to airway remodeling, exacerbation frequency, and the inflammatory cascade.MethodsWe conducted a comprehensive literature review of recent studies that discuss the pathophysiological role of eosinophils in COPD and the clinical outcomes associated with modulating eosinophilic activity.ResultsEosinophils contribute to COPD progression by releasing cytotoxic proteins and cytokines that intensify the inflammatory response and airway alterations. Targeting specific eosinophil-related cytokines with monoclonal antibodies or receptor antagonists may potentially reduce eosinophil counts, mitigate exacerbations, and improve patient outcomes.ConclusionUnderstanding eosinophilic involvement in COPD can facilitate the development of precision medicine approaches, offering more tailored and effective treatment options. Future research should continue to focus on the integration of eosinophil biomarkers in clinical practice to enhance therapeutic decisions and management strategies for COPD patients.

26 keywords...

hide…